Previous studies have reported changes in the concentrations of several neurometabolites in Alzheimer’s disease (AD). Nevertheless, group differences of these metabolites between healthy controls, mild cognitively impaired, and AD patients remain small. The transition to ultrahigh fields enables the assessment of further metabolites, and some of them, like GABA and glutamate, have been observed to change in AD. In this study, the combination of several metabolite concentrations associated with AD into a product-ratio to serve as a stronger MRS biomarker for Alzheimer’s than individual concentrations of metabolites, and their relationship with volume of brain structures and memory performance is investigated.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords